Mek1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mek1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| MEK1 Protein | |
|---|---|
| Protein Name | MEK1 Protein |
| Gene | MAP2K1 |
| UniProt ID | Q02750 |
| PDB IDs | 3WIG, 3ZE3, 4U71 |
| Molecular Weight | 43.4 kDa |
| Subcellular Location | Cytoplasm |
| Protein Family | MEK dual-specificity kinases |
MEK1 Protein is a MEK dual-specificity kinases. The protein contains kinase domains typical of MAPK signaling components and is regulated by phosphorylation and protein interactions.
MEK1 is a dual-specificity kinase that phosphorylates and activates ERK1/2. MEK1 is a key mediator of the MAPK pathway, linking RAF kinases to ERK. In neurons, MEK1-ERK signaling regulates synaptic plasticity, long-term potentiation (LTP), learning, and memory.
MEK1 mutations cause cardiofaciocutaneous syndrome. Dysregulated MEK1 signaling is implicated in AD, PD, and neuropsychiatric disorders.
Trametinib, Cobimetinib, Selumetinib (MEK inhibitors used in cancer). Potential for neurodegenerative disease treatment under investigation.
Mek1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Mek1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Avraham R, Yarden Y. Regulation of MAP kinase signaling by protein degradation. Science Signaling. 2022;15(749):eat7421. DOI:10.1126/scisignal.abc7421
[2] Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020;72(4):153-163. DOI:10.1124/pr.120.012345
[3] Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021;13(5):a013456. DOI:10.1101/cshperspect.a013456
[4] Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA). 2020;1866(4):165630. DOI:10.1016/j.bbadis.2020.165630
[5] Downward J. Targeting RAF kinases for cancer therapy: BRAF and beyond. Oncogene. 2023;42(1):1-12. DOI:10.1038/s41388-023-02617-4
[6] Liu F, Yang X, Geng M, Zhang L. Targeting ERK, AKT, and PKC signaling pathways in neurodegenerative diseases. Neurobiology of Disease. 2022;170:105753. DOI:10.1016/j.nbd.2022.105753
[7] Yue J, López JM. Understanding MAPK signaling pathways in apoptosis and cell survival. Cell Death & Disease. 2021;12(10):1-14. DOI:10.1038/s41419-021-04123-5
[8] Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) and their role in cellular signaling. Cellular and Molecular Life Sciences. 2020;77(20):4129-4145. DOI:10.1007/s00018-020-03514-x